Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $1.94 | $0.82 | 72.77% | 111.7M | - | $0.88$55.77 |
| ANTX | An2 Therapeutics | $4.89 | $2.04 | 71.40% | 14.1M | $78M | $1.00$4.94 |
| DTCK | Davis Commodities | $2.37 | $0.94 | 65.71% | 22.3M | $39M | $1.32$137.80 |
| TURB | Turbo Energy | $6.09 | $2.31 | 61.11% | 17.5M | $42M | $0.57$20.45 |
| XENE | Xenon Pharmaceuticals | $61.71 | $19.77 | 47.14% | 458K | $3.5B | $26.74$62.40 |
| HIMS | Hims & Hers Health | $22.27 | $6.53 | 41.49% | 4.5M | $3.6B | $13.74$70.43 |
| RLMD | Relmada Therapeutics | $6.06 | $1.61 | 36.18% | 988.8K | $326M | $0.24$6.51 |
| ATRA | Atara Biotherapeutics | $6.74 | $1.57 | 30.37% | 45.9K | $37M | $3.92$19.15 |
| DNTH | Dianthus Therapeutics | $82.45 | $17.25 | 26.46% | 89.6K | $2.8B | $13.37$84.78 |
| RNAC | Cartesian Therapeutics | $8.59 | $1.74 | 25.40% | 9K | $178M | $5.98$18.80 |
| NERV | Minerva Neurosciences | $7.51 | $1.50 | 24.88% | 195K | $260M | $1.15$12.46 |
| PLYX | Polaryx Therapeutics | $3.39 | $0.65 | 23.72% | 487.9K | $130M | $2.20$48.91 |
| AGCC | Agencia Comercial Spirits | $22.25 | $4.14 | 22.86% | 1.3K | $623M | $3.66$22.88 |
| QURE | uniQure | $17.53 | $3.26 | 22.84% | 9M | $879M | $7.76$71.50 |
| EDIT | Editas Medicine | $2.43 | $0.43 | 21.50% | 108.6K | $195M | $0.91$4.54 |
| RGNX | Regenxbio | $10.42 | $1.77 | 20.46% | 1M | $438M | $5.04$16.19 |
| LSTA | Lisata Therapeutics | $5.04 | $0.86 | 20.45% | 319.7K | $37M | $1.81$5.06 |
| BEG | Themes ETF Trust - Leverage Shares 2x Long Be Daily ETF | $30.91 | $4.77 | 18.23% | 29.3K | - | $10.89$50.61 |
| KC | Kingsoft Cloud | $14.10 | $2.11 | 17.60% | 85.1K | $3.5B | $10.29$19.57 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $4.08 | $0.61 | 17.58% | 24.3M | - | $0.95$20.92 |
| OVID | Ovid Therapeutics | $2.23 | $0.32 | 16.75% | 80.6K | $249M | $0.24$2.27 |
| VRTL | GraniteShares ETF Trust - GraniteShares 2x Long Vrt Daily ETF | $115.39 | $16.50 | 16.68% | 5.2K | - | $7.57$119.89 |
| NBTX | Nanobiotix | $39.50 | $5.51 | 16.21% | 1.7K | $1.6B | $2.95$39.55 |
| DDD | 3D Systems | $2.27 | $0.31 | 15.56% | 77.1K | $252M | $1.32$3.80 |
| LXEO | Lexeo Therapeutics | $7.84 | $0.99 | 14.45% | 48.9K | $500M | $1.45$10.99 |
| CAMP | Camp4 Therapeutics | $4.78 | $0.58 | 13.69% | 31.1K | $218M | $1.31$7.31 |
| HUHU | Huhutech International Group | $7.11 | $0.29 | 4.25% | 113 | $176M | $2.95$12.20 |
| MAYS | J.w. Mays | $45.69 | $0.69 | 1.53% | 1.3K | $91M | $32.32$61.99 |
Related Articles
Featured Article
Hims & Hers Stock Pops 40%: Everything You Need to Know
Travis Hoium|Mar 9, 2026
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Selena Maranjian|Nov 24, 2025
It has grown wildly, and it could keep growing.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
